CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 490 enrolled
Drug / intervention
Sarecyclinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02413346
NCT02413346Phase 3Completed
CompareCT.gov

A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris

Almirall, S.A.·interventional·Posted Apr 9, 2015·Updated Feb 1, 2019

In Brief

A Phase 3 clinical trial evaluating Sarecycline for Acne Vulgaris. Completed, enrolled 490 participants across 56 sites.

Detailed Summary

Open-label study will evaluate the safety of an approximate 1.5 mg/kg/day dose of oral sarecycline in the long-term treatment of participants with moderate to severe facial acne vulgaris.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
CollaboratorsAllergan

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 9, 2015
Enrollment StartMar 20, 2015
Primary CompletionAug 26, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 11.2 years ago

Interventions

Sarecyclinedrug

Administered based on participant's body weight.